HC Wainwright & Co. Maintains Buy on Longboard Pharmaceuticals, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reaffirmed a Buy rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and increased the price target from $25 to $60.

January 08, 2024 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longboard Pharmaceuticals' Buy rating is maintained by HC Wainwright & Co., with a significant price target increase from $25 to $60.
The reaffirmation of a Buy rating combined with a substantial increase in the price target from $25 to $60 by a reputable analyst firm like HC Wainwright & Co. is likely to be viewed positively by investors and could lead to a short-term increase in the stock price of Longboard Pharmaceuticals. The new price target suggests a significant upside potential from the current trading level, which may attract investor interest and buying pressure.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100